Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Of BBR 3464 As Treatment In Patients With Sensitive Or Refractory Small Cell Lung Cancer After One Prior Chemotherapy Regimen

NCT00014547 is registered in ClinicalTrials.gov with Theradex as lead sponsor.

NCT NCT00014547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00014547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Of BBR 3464 As Treatment In Patients With Sensitive Or Refractory Small Cell Lung Cancer After One Prior Chemotherapy Regimen
Lead sponsor
Theradex
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer